Taxol is one of the most potent anticancer agents used in the treatment of breast and ovarian cancers [1] . It presents disadvantages such as low water-solubility and toxicity toward normal tissues. To date many efforts have been made to modify taxol chemically in order to create a more soluble and more easily delivered drug [2] [3] [4] . Taxol prodrugs, that incorporate acids, have attracted much attention, because an ester linkage improves the solubility of taxol and can be hydrolyzed by hydrolytic enzymes to release taxol. However, little attention has been paid to synthesis of ester-linked taxol-glycoside conjugates as water-soluble taxol prodrugs, which employ enzymatic cleavage as their mode of activation. On the other hand, convenient drug delivery system using hepatitis B virus surface antigen L particles (bionanocapsules) has been recently reported [5] . However, this system is not effective for delivering taxol, because the present nanoparticles can incorporate only soluble drugs.
On continuing the study to develope the technology for delivering taxol, we report the synthesis of highly water-soluble glycolyl-esterlinked taxol-oligosaccharide conjugate, i.e., 7-glycolyltaxol 2''-O--maltotrioside, as taxol-prodrug and new delivery system for taxol-prodrug using hepatitis B virus envelope L particles (bionanocapsules) and antibody-attached particles (hybrid-bionanocapsules).
Enzymatic glycosylation of 7-glycolyltaxol 2''-O--D-glucoside was carried out using cyclodextrin glucanotransferase (CGTase), which produces -(1→4)-glucooligosaccharide, as biocatalyst. Incubation of 7-glycolyltaxol 2''-O--D-glucoside with CGTase (Amano Pharmaceutical Co. Ltd) in the presence of soluble starch in sodium phosphate buffer (pH 7.0) for 24 h provided oligosaccharide products 1-4 [1 (15% yield), 2 (10%), 3 (7%), 4 (5%), and other products (46%) with higher molecular weight]. Next, oligosaccharide products were subjected to the hydrolysis using -glucosidase. Reaction of oligosaccharides with -glucosidase (Amano Pharmaceutical Co. Ltd) in sodium phosphate buffer (pH 7.0) for 12 h gave oligosaccharide products [1 (29% yield), 2 (18%), 3 (2%), 4 (1%), and other products (7%) with higher molecular weight]. The chemical structure of the product 2 was established by NMR spectroscopic analyses after purification by HPLC, and was identified as 7-glycolyltaxol 2''-O--maltotrioside ( Fig. 1 ) with high water-solubility.
Highly water-soluble taxol-prodrug, 7-glycolyltaxol 2''-O--maltotrioside, was electroporated into bio-nanocapsules. The filtrate of bio-nanocapsules solution after centrifugation was analyzed by HPLC to clarify the efficient incorporation of taxol-prodrug in bionanocapsules, and no taxol-prodrug was detected. The mean particle size of bio-nanocapsules was approximately 140 nm. Encapsulation of 7-glycolyltaxol 2''-O--maltotrioside into bio-nanocapsules showed 21% of encapsulation efficiency (EE). The cytotoxic activity of taxol-prodrug incorporated in bio-nanocapsules toward human hepatocellular carcinoma NuE cells was examined. The cytotoxicity of both 7-glycolyltaxol 2''-O--maltotrioside and 7-NPC Natural Product Communications 2''-O--maltotrioside incorporated in bionanocapsules was increased dose-dependently. The cytotoxic activity of 7-glycolyltaxol 2''-O--maltotrioside incorporated in bionanocapsules (IC 50 =28 M) was higher than 7-glycolyltaxol 2''-O--maltotrioside itself (IC 50 =60 M).
Next, taxol-prodrug 7-glycolyltaxol 2''-O--maltotrioside was electroporated into hybrid-bio-nanocapsules. To clarify the efficient incorporation of taxol-prodrug in the hybrid-bio-nanocapsules, the filtrate of hybrid-bio-nanocapsules solution was analyzed by HPLC and no taxol-prodrug was detected. The mean particle size of hybrid-bio-nanocapsules was approximately 170 nm. Encapsulation of 7-glycolyltaxol 2''-O--maltotrioside into hybrid-bionanocapsules showed 12% of encapsulation efficiency (EE). Human glioma cells were treated with 7-glycolyltaxol 2''-O--maltotrioside and 7-glycolyltaxol 2''-O--maltotrioside incorporated in hybridbio-nanocapsules. The cytotoxicity of both 7-glycolyltaxol 2''-O--maltotrioside and 7-glycolyltaxol 2''-O--maltotrioside incorporated in hybrid-bio-nanocapsules was increased dose-dependently. At each concentration tested, the cytotoxic activity of 7-glycolyltaxol 2''-O--maltotrioside (IC 50 =46 M) incorporated in hybrid-bionanocapsules was higher than 7-glycolyltaxol 2''-O--maltotrioside (IC 50 =76 M).
Thus, an ester-linked oligosaccharide prodrug of taxol i.e., 7-glycolyltaxol 2''-O--maltotrioside, was synthesized by enzymatic procedure. The bio-nanocapsules and hybrid-bio-nanocapsules containing 7-glycolyltaxol 2''-O--maltotrioside exhibited effective anticancer activity, respectively.
Experimental

Preparation of bio-nanocapsules containing glycoside prodrug of taxol and MTT assay: The hepatitis B virus surface antigen L particles (bio-nanocapsules) were overexpressed in Saccharomyces cerevisiae AH22R
-carrying hepatitis B virus envelope L expression plasmid pGLDLIIP39-RcT and purified by precipitation with polyethylene glycol 6000, CsCl isopycnic ultracentrifugation and sucrose density gradient ultracentrifugation. About 4 mg of purified L particles were obtained from wet wt. 20 g of the yeast cells. The solution including purified L particles was concentrated by Vinapspin Concentrator-1000,000MWCO (Vivascience Ltd.) to 200 ng/mL. The sensitivity of human hepatocellular carcinoma NuE cells to 7-glycolyltaxol 2''-O--maltotrioside or 7-glycolyltaxol 2''-O--maltotrioside electroporated into L particles was determined as follows. Cells were diluted with culture medium to the seeding density (10 5 cells/mL), suspended in 96-well tissue culture plates (100 L/well), preincubated at 37°C for 4 h, and then treated for 24 h with 7-glycolyltaxol 2''-O--maltotrioside or 7-glycolyltaxol 2''-O--maltotrioside electroporated into L particles at various concentrations to obtain a dose-response curve for each compound. After incubation, 20 L MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, yellow tetrazole) solution (2.5 mg/mL) was added to each well and the plates were further incubated for 4 h. Absorbance at 570 nm was measured with a microplate reader model 450 (BIO-RAD). Dose-response curves were plotted on a semi-log scale as percentage of the cell numbers in control cultures not exposed to test compounds.
Preparation of hybrid-bio-nanocapsules containing glycoside prodrug of taxol and MTT assay: The pre-S1 region of L protein was replaced with an IgG Fc binding motif (ZZtag), which is the two-helix domain of protein A from Staphylococcus aureus. Bionanocapsules were incubated with rhodamin B isothiocyanate (RITC, 1 mg/mL) at room temperature for 15 min and the mixture was further reacted at 4°C overnight in phosphate buffered saline (PBS). After incubation, bio-nanocapsules were incubated with ethanolamine (2.5 mM) for 2 h at 4°C. The buffer solution of the bio-nanocapsules was replaced by PBSE. The RITC-conjugated bio-nanocapsules were mixed with monoclonal anti-epidermal growth factor receptor (EGFR) antibodies for 1 h at 4°C to give hybrid-bio-nanocapsules. The sensitivity of human glioma cell line Gli36 to 7-glycolyltaxol 2''-O--maltotrioside or 7-glycolyltaxol 2''-O--maltotrioside electroporated into hybrid-bio-nanocapsules was determined. Cells were diluted with culture medium to the seeding density (10 5 cells/mL), suspended in 96-well tissue culture plates (100 L/well), preincubated at 37°C for 4 h, and then treated for 24 h with 7-glycolyltaxol 2''-O--maltotrioside or 7-glycolyltaxol 2''-O--maltotrioside electroporated into hybrid-bio-nanocapsules at various concentrations to obtain a dose-response curve for each compound. After incubation, 20 L MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, yellow tetrazole) solution (2.5 mg/mL) was added to each well and the plates were further incubated for 4 h. Absorbance at 570 nm was measured with a microplate reader model 450 (BIO-RAD). Dose-response curves were plotted on a semi-log scale as percentage of the cell numbers in control cultures not exposed to test compounds.
Particle size and EE value of bio-nanocapsules and hybrid-bionanocapsules: The particle size of bio-nanocapsules and hybridbio-nanocapsules was determined by dynamic light scattering with an ELS-8000 microscope. EE was calculated as the ratio of the amount of 7-glycolyltaxol 2''-O--maltotrioside encapsulated into bio-nanocapsules and hybrid-bio-nanocapsules to the initial amount of the drug. The amount of encapsulated 7-glycolyltaxol 2''-O--maltotrioside was evaluated by C 18 reverse-phase HPLC at a flow rate of 1 mL/min.
